Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vivos Therapeutics (NASDAQ: VVOS) reported third-quarter 2026 revenue of $6.4 million, with a narrower operating loss than a year earlier. Revenue rose 24% sequentially but fell from $6.8 million a year earlier. Operating loss narrowed 18% to $3.9 million as operating expenses fell 17%. Gross margin declined to 52% from 58%. Net loss narrowed to $2.0 million, including approximately $2.9 million of income from reversing an Employee Retention Credit liability.
Nine-month revenue rose to $16.7 million from $13.6 million, while operating loss widened to $15.3 million from $13.5 million. Cash was $247,000 at September 30, down from $2,029,000 at year-end. Vivos exchanged approximately $6.1 million of secured debt for equity during 2026. It completed the SOD Sciences transaction October 16 and regained Nasdaq equity compliance October 20, subject to continued monitoring. Vivos expects new clinical initiatives to contribute to revenue and margins beginning in Q4 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointSenior secured debt of approximately $6.1 million was exchanged for equity during 2026. 2.2× market cap
- Major pointVivos estimates it has eliminated $5 million or more in annual operating costs, with further efficiencies underway.
- Moderate pointThird-quarter revenue rose 24% sequentially to $6.4 million from $5.2 million.
- Moderate pointThird-quarter operating loss narrowed 18% to $3.9 million from $4.7 million a year earlier.
- Moderate pointThird-quarter net loss narrowed to $1.971 million from $5.400 million; approximately $2.9 million reflected a liability reversal. 1× market cap
- Moderate pointNasdaq stockholders’ equity compliance was regained October 20, 2026.
10 minor points
- Minor pointThird-quarter operating expenses fell 17% to $7.2 million from $8.7 million a year earlier.
- Minor pointThird-quarter loss per share narrowed to $0.07 from $0.49 a year earlier.
- Minor pointNine-month revenue increased to $16.708 million from $13.619 million a year earlier.
- Minor pointService revenue rose 1% in Q3 to $4.6 million and 57% over nine months to $12.1 million.
- Minor pointNine-month gross profit increased to $9.326 million from $7.554 million; gross margin rose to 56% from 55%.
- Minor pointNine-month loss per share narrowed to $0.77 from $1.49 a year earlier.
- Minor pointTotal liabilities declined to $20.693 million at September 30 from $26.702 million at December 31, 2025.
- Minor pointStockholders’ equity reached $2.360 million at September 30, versus a $1.490 million deficit at year-end.
- Minor pointSOD Sciences transaction completed October 16, 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.Vivos expects clinical initiatives to contribute to revenue and margins beginning Q4 2026, increasingly throughout 2027.
Negative
- Major pointCash fell to $247,000 at September 30, 2026, from $2,029,000 at December 31, 2025.
- Major pointCurrent liabilities of $16.163 million exceeded current assets of $3.508 million at September 30, 2026.
- Major pointCommon shares outstanding increased to 33,820,768 at September 30 from 9,286,609 at year-end, diluting existing holders.
- Moderate pointThird-quarter revenue declined to $6.414 million from $6.783 million a year earlier.
- Moderate pointThird-quarter gross profit fell to $3.314 million from $3.937 million; gross margin declined to 52% from 58%.
- Moderate pointNine-month operating expenses increased to $24.662 million from $21.066 million, primarily reflecting Nevada center establishment costs.
- Moderate pointNine-month operating loss widened to $15.336 million from $13.512 million a year earlier.
4 minor points
- Minor pointProduct revenue declined to $1.772 million in Q3 and $4.567 million over nine months, versus $2.195 million and $5.893 million.
- Minor pointNine-month net loss widened to $15.245 million from $14.276 million a year earlier.
- Minor pointOther expense increased to $981,000 in Q3 and $3.199 million over nine months, versus $679,000 and $850,000.
- Minor pointNasdaq equity compliance remains subject to continued monitoring.
News Explained
At September thirtieth, cash represented seven point two days of third-quarter operating cash outflow at that quarter’s rate.
At
Quarter-end cash of
Sources and calculations
- Vivos Therapeutics third-quarter 2026 results release (2026-11-16)
- Dilution definition (version supplied)
- Vivos Therapeutics 2026 third-quarter fundamentals (2026Q3)
- Available liquidity against the last reported quarterly operating outflow, in days at that rate $247,000 / ($3,176,000 / 92) = 7.2 days
Key Figures
- Q3 revenue
- $6.4 million
- Q3 2026; up 24% from $5.2 million in Q2 2026
- Nine-month revenue
- $16.7 million
- Nine months ended September 30, 2026; compared with $13.6 million in 2025
- Q3 operating loss
- $3.9 million
- Q3 2026; improved 18% from $4.7 million in Q3 2025
- Q3 net loss
- $2.0 million
- Q3 2026; compared with $5.4 million in Q3 2025
- Cash and cash equivalents
- $0.2 million
- At September 30, 2026; compared with $2.0 million at December 31, 2025
- Stockholders’ equity
- $2.4 million
- At September 30, 2026; compared with a $1.5 million deficit at December 31, 2025
- Q3 gross margin
- 52%
- Q3 2026; compared with 58% in Q3 2025
- Total liabilities
- $20.7 million
- At September 30, 2026; down from $26.7 million at December 31, 2025
Previous Earnings Reports
-
Q2 revenue grew 35% year over year, with a $5.5 million net loss.
-
Revenue rose 70% year over year, while net loss widened to $7.8 million.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
osa medical
cpap medical
eeg medical
510(k) clearance regulatory
form 10-q regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Revenue rises
Management to Host Conference Call today at 5:00 pm ET
LITTLETON, Colo., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep related breathing disorders, today reported financial results and operating highlights for the three and nine months ended September 30, 2026.
Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer, stated, “During the third quarter of 2026, we took decisive steps to reduce costs and strengthen our balance sheet. Our operating loss improved
Mr. Huntsman continued, “We are also pursuing a number of clinical initiatives at our SCN and SAMC centers, including EEG testing and treatment for insomnia and other non-OSA sleep disorders, the distribution and set-up of PAP and CPAP treatments, and remote patient monitoring of CPAP users, together with the renegotiation of our payer contracts. We expect these initiatives to contribute to revenue and margins beginning in the fourth quarter of 2026 and increasingly throughout 2027.”
Third Quarter 2026 Financial and Operating Summary
- Revenue was
$6.4 million for the third quarter of 2026, up24% from$5.2 million in the second quarter of 2026, and$16.7 million for the nine months ended September 30, 2026, compared to$6.8 million and$13.6 million for the three and nine months ended September 30, 2025. Third quarter service revenue increased1% to$4.6 million , while product revenue decreased to$1.8 million from$2.2 million , reflecting our strategic pivot away from appliance sales to dentists in our Vivos Integrated Provider (VIP) program. For the nine months, service revenue increased57% to$12.1 million , primarily attributable to sleep testing and resulting treatment services in our Nevada operations; - Gross profit was
$3.3 million for the third quarter of 2026 and$9.3 million for the nine months ended September 30, 2026, compared to$3.9 million and$7.6 million for the comparable periods in 2025. The third quarter decrease was due to lower product revenue and higher cost of sales, while the nine-month increase was due to stronger service revenue; - Gross margin was
52% in the third quarter of 2026 compared to58% in the third quarter of 2025, due to the decrease in product revenue. For the nine months ended September 30, 2026, gross margin was56% compared to55% in the same period in 2025; - Operating expenses for the third quarter ended September 30, 2026 were
$7.2 million , a17% decrease compared to$8.7 million in the same period a year ago, reflecting a$1.4 million reduction in general and administrative expenses, driven primarily by lower professional fees, equipment maintenance and office expenses, as well as lower sales and marketing expenses. For the nine months ended September 30, 2026, operating expenses were$24.7 million versus$21.1 million in the same period in 2025, an increase driven primarily by the costs of establishing our two Sleep and Airway Medicine Centers in Las Vegas and Henderson, Nevada; - The third quarter 2026 operating loss improved
18% to$3.9 million , compared to$4.7 million in the third quarter of 2025. For the nine months ended September 30, 2026, the operating loss was$15.3 million compared to$13.5 million for the nine months ended September 30, 2025. - Net loss for the third quarter of 2026 was
$2.0 million , compared to$5.4 million in the third quarter of 2025, and included approximately$2.9 million of other income from the reversal of our previously recorded Employee Retention Credit liability; - At September 30, 2026, cash and cash equivalents were
$0.2 million and total stockholders’ equity was$2.4 million , compared to cash and cash equivalents of$2.0 million and a stockholders’ deficit of$1.5 million as of December 31, 2025. Total liabilities decreased to$20.7 million at September 30, 2026 from$26.7 million at December 31, 2025. Subsequent to quarter end, on October 16, 2026, we completed our SOD Sciences transaction, and on October 20, 2026, Nasdaq notified us that we had regained compliance with its minimum stockholders’ equity requirement, subject to Nasdaq’s continued monitoring.
Investor Call and 10-Q Filing
Vivos encourages investors and other interested parties to join its conference call today at 5:00 p.m. Eastern time. Management will discuss further details on topics including Vivos’ strategic initiatives and their anticipated effect on near-term revenue growth and cash burn.
To access Vivos’ investor conference call, please dial (800) 717-1738, or for international callers, (646) 307-1865. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The Access ID for the replay is 1177865. The replay will be available until Monday, November 30, 2026.
A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations. An online archive of the webcast will be available at Vivos’ website for 30 days following the call.
In addition, further information on Vivos’ financial results is included on the attached unaudited condensed consolidated balance sheets and statements of operations, and additional information about Vivos’ financial performance is provided in Vivos’ Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2026, which has been filed with the Securities and Exchange Commission (“SEC”). This press release discusses certain financial information for the second quarter ended June 30, 2026, and more information about our results for the second quarter are included in Vivos’ Quarterly Report on Form 10-Q for the three and six months ended June 30, 2026, which has been filed with the SEC. The full 10-Q reports will be available on the SEC Filings section of the Investor Relations section of Vivos’ website at https://vivos.com/investor-relations.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (Nasdaq: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices were the first oral appliances to receive FDA 510(k) clearance for treating severe OSA in adults and the flagship DNA appliance is the first oral appliance to receive FDA clearance for treating moderate to severe OSA in children.
OSA and insomnia affect over 1 billion adults aged 30-69 years old worldwide, yet
Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly.
Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.
For more information, visit www.vivos.com.
Cautionary Note Regarding Forward‑Looking Statements
This press release, the conference call referred to herein, and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995) concerning future events. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal”, “will”, “would”, “could”, “potential”, “continue” and variations of such words and similar expressions are intended to identify forward-looking statements.
These statements involve significant known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos' control. Actual results (including the actual benefits of the cost reductions, clinical initiatives and other matters described herein and actual revenue and cash flow results) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to implement revenue, sales and marketing strategies and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (iv) the risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all, or maintain its Nasdaq listing due to, among other things, its ability to meet Nasdaq’s stockholders’ equity and minimum bid price requirements; (v) the risk that Vivos will not have enough cash to fund its operations and continue as a going concern; (vi) the risk that the final accounting for the SOD Sciences transaction, or review by Nasdaq or Vivos’ independent registered public accounting firm, results in a smaller increase in stockholders’ equity than expected; (vii) the risk that Vivos will not regain compliance with Nasdaq’s minimum bid price requirement by December 2, 2026 or any extended deadline, or that stockholders will not approve the proposed reverse stock split, or that the closing bid price of Vivos’ common stock will be
Except to the extent required by law, Vivos expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos' expectations with respect thereto or any change in events, conditions, or circumstances on which any such statement is based.
Vivos Investor Relations Contact:
Jennifer Hauser, Executive Assistant to the CEO
jhauser@vivoslife.com
720-927-3125
-Financial Tables Follow-
| VIVOS THERAPEUTICS INC. | |||||||||||||||
| Unaudited Condensed Consolidated Statements of Operations | |||||||||||||||
| (In Thousands, Except Per Share Amounts) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenue | |||||||||||||||
| Product revenue | $ | 1,772 | $ | 2,195 | $ | 4,567 | $ | 5,893 | |||||||
| Service revenue | 4,642 | 4,588 | 12,141 | 7,726 | |||||||||||
| Total revenue | 6,414 | 6,783 | 16,708 | 13,619 | |||||||||||
| Cost of sales (exclusive of depreciation and amortization shown separately below) | 3,100 | 2,846 | 7,382 | 6,065 | |||||||||||
| Gross profit | 3,314 | 3,937 | 9,326 | 7,554 | |||||||||||
| Operating expenses | |||||||||||||||
| General and administrative | 6,450 | 7,884 | 22,533 | 19,181 | |||||||||||
| Sales and marketing | 210 | 403 | 614 | 1,018 | |||||||||||
| Depreciation and amortization | 550 | 384 | 1,515 | 867 | |||||||||||
| Total operating expenses | 7,210 | 8,671 | 24,662 | 21,066 | |||||||||||
| Operating loss | (3,896 | ) | (4,734 | ) | (15,336 | ) | (13,512 | ) | |||||||
| Non-operating income (expense) | |||||||||||||||
| Other expense | (981 | ) | (679 | ) | (3,199 | ) | (850 | ) | |||||||
| Other income | 2,906 | 13 | 3,290 | 86 | |||||||||||
| Loss before income taxes | (1,971 | ) | (5,400 | ) | (15,245 | ) | (14,276 | ) | |||||||
| Net loss | $ | (1,971 | ) | $ | (5,400 | ) | $ | (15,245 | ) | $ | (14,276 | ) | |||
| Net loss attributable to non-controlling interest | (26 | ) | - | (137 | ) | - | |||||||||
| Net loss attributable to stockholders | $ | (1,945 | ) | $ | (5,400 | ) | $ | (15,108 | ) | $ | (14,276 | ) | |||
| Net loss per share (basic and diluted) | $ | (0.07 | ) | $ | (0.49 | ) | $ | (0.77 | ) | $ | (1.49 | ) | |||
| Weighted average number of shares of Common Stock outstanding (basic and diluted) | 26,528,253 | 10,963,590 | 19,658,339 | 9,557,368 | |||||||||||
See the notes to the unaudited condensed consolidated financial statements in Vivos’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.
| VIVOS THERAPEUTICS INC. | |||||||
| Unaudited Condensed Consolidated Balance Sheets | |||||||
| (In Thousands, Except Per Share Amounts) | |||||||
| September 30, 2026 | December 31, 2025 | ||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 247 | $ | 2,029 | |||
| Accounts receivable, net of allowance of | 2,370 | 1,581 | |||||
| Prepaid expenses and other current assets | 891 | 774 | |||||
| Total current assets | 3,508 | 4,384 | |||||
| Long-term assets | |||||||
| Goodwill | 8,572 | 8,572 | |||||
| Property and equipment, net | 3,347 | 3,757 | |||||
| Operating lease right-of-use asset | 3,624 | 4,166 | |||||
| Intangible assets, net | 3,438 | 4,045 | |||||
| Deposits and other | 367 | 228 | |||||
| Total assets | $ | 22,856 | $ | 25,152 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY/(DEFICIT) | |||||||
| Current liabilities | |||||||
| Accounts payable | $ | 2,739 | $ | 1,679 | |||
| Accrued expenses | 8,819 | 5,988 | |||||
| Contract liabilities | 72 | 479 | |||||
| Current portion of operating lease liability | 850 | 672 | |||||
| Current portion of financing lease liability | 57 | 55 | |||||
| Current portion of debt | 1,502 | 8,353 | |||||
| Other current liabilities | 2,124 | 850 | |||||
| Total current liabilities | 16,163 | 18,076 | |||||
| Long-term liabilities | |||||||
| Employee retention credit liability | - | 2,904 | |||||
| Operating lease liability, net of current portion | 3,198 | 3,840 | |||||
| Financing lease liability, net of current portion | 69 | 113 | |||||
| Debt, net of current portion | 313 | 469 | |||||
| Other liabilities | 950 | 1,300 | |||||
| Total liabilities | 20,693 | 26,702 | |||||
| Commitments and contingencies | - | - | |||||
| Stockholders’ equity/(deficit) | |||||||
| Preferred Stock, | $ | - | $ | - | |||
| Preferred Stock – additional paid in capital | 3,605 | - | |||||
| Common Stock, | 3 | 1 | |||||
| Additional paid-in capital | 139,217 | 123,866 | |||||
| Accumulated deficit | (140,465 | ) | (125,357 | ) | |||
| Total stockholders’ equity/(deficit) | 2,360 | (1,490 | ) | ||||
| Non-controlling interest | (197 | ) | (60 | ||||
| Total equity/(deficit) | 2,163 | (1,550 | ) | ||||
| Total liabilities and equity/(deficit) | $ | 22,856 | $ | 25,152 | |||
See the notes to the unaudited condensed consolidated financial statements in Vivos’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Vivos Therapeutics’ third-quarter 2026 financial results?
Vivos reported $6.4 million in revenue, a $3.9 million operating loss and a $2.0 million net loss. Revenue rose 24% from the second quarter but declined from $6.8 million a year earlier. Net loss included approximately $2.9 million of other income from reversing an Employee Retention Credit liability.
Did VVOS regain compliance with Nasdaq’s stockholders’ equity requirement?
Nasdaq notified Vivos on October 20, 2026, that it had regained compliance with the minimum stockholders’ equity requirement, subject to continued monitoring. The notification followed completion of the SOD Sciences transaction on October 16, 2026.
What clinical initiatives is Vivos pursuing to improve revenue and margins?
Vivos is pursuing EEG testing and treatment for insomnia and other non-OSA sleep disorders, PAP and CPAP treatment distribution and setup, and remote monitoring of CPAP users at its SCN and SAMC centers, alongside payer-contract renegotiations. The company expects contributions to revenue and margins beginning in the fourth quarter of 2026 and increasingly throughout 2027.